Lukas Stolz, Charles Davidson, Volker Rudolph, Jörg Hausleiter
{"title":"三尖瓣干预后残余三尖瓣反流：我们知道什么？","authors":"Lukas Stolz, Charles Davidson, Volker Rudolph, Jörg Hausleiter","doi":"10.1002/ejhf.3675","DOIUrl":null,"url":null,"abstract":"<h2> Introduction</h2>\n<p>Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.<span><sup>1</sup></span> Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge repair (T-TEER) is the most commonly used treatment technique which has shown QoL improvement beyond medical treatment in randomized controlled settings.<span><sup>2, 3</sup></span> Due to advancements in transcatheter TV replacement (TTVR)<span><sup>4-8</sup></span> which is able to almost completely eliminate TR, a debate has arisen about how much TR reduction is desirable, safe and necessary.</p>\n<p>Over the past months and years, the body of evidence on this question has become more substantial. In this viewpoint, we therefore present our perspective on the topic based on the data available today.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"137 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Residual tricuspid regurgitation after tricuspid valve interventions: What do we know?\",\"authors\":\"Lukas Stolz, Charles Davidson, Volker Rudolph, Jörg Hausleiter\",\"doi\":\"10.1002/ejhf.3675\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2> Introduction</h2>\\n<p>Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.<span><sup>1</sup></span> Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge repair (T-TEER) is the most commonly used treatment technique which has shown QoL improvement beyond medical treatment in randomized controlled settings.<span><sup>2, 3</sup></span> Due to advancements in transcatheter TV replacement (TTVR)<span><sup>4-8</sup></span> which is able to almost completely eliminate TR, a debate has arisen about how much TR reduction is desirable, safe and necessary.</p>\\n<p>Over the past months and years, the body of evidence on this question has become more substantial. In this viewpoint, we therefore present our perspective on the topic based on the data available today.</p>\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"137 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3675\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3675","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Residual tricuspid regurgitation after tricuspid valve interventions: What do we know?
Introduction
Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.1 Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge repair (T-TEER) is the most commonly used treatment technique which has shown QoL improvement beyond medical treatment in randomized controlled settings.2, 3 Due to advancements in transcatheter TV replacement (TTVR)4-8 which is able to almost completely eliminate TR, a debate has arisen about how much TR reduction is desirable, safe and necessary.
Over the past months and years, the body of evidence on this question has become more substantial. In this viewpoint, we therefore present our perspective on the topic based on the data available today.
期刊介绍：
European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
